High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor

被引:11
作者
Fukutomi, Tatsuya [1 ]
Takeda, Yutaka [2 ]
Suzuki, Shogo [2 ]
Ito, Tatsuya [2 ]
Joh, Takashi [3 ]
Itoh, Makoto [4 ]
机构
[1] Asuke Hosp, Dept Internal Med & Cardiol, Toyota, Aichi 4442351, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Cardiorenal Med & Hypertens, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi 4678601, Japan
[4] Nagoya Keizai Univ, Fac Human Life & Sci, Dept Hlth & Nutr Sci, Inuyama, Aichi 4848504, Japan
关键词
Pitavastatin; High density lipoprotein-cholesterol; Apolipoprotein A-I; ATORVASTATIN; SIMVASTATIN;
D O I
10.1016/j.ijcard.2008.11.130
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although a low level of high density lipoprotein-cholesterol (HDL-C) is an important risk factor for coronary heart disease, few available agents are capable of significantly increasing HDL-C. This multicenter study demonstrated that administration of pitavastatin, a new HMG-CoA reductase inhibitor, significantly and persistently increased HDL-C (from 36.0 ± 5.9 to 40.5 ± 9.1 mg/dL: p < 0.001) and apolipoprotein A-I levels (from 108.4 ± 18.0 to 118.7 ± 19.3 mg/dL: p < 0.01) in 43 hypercholesterolemic patients with low HDL-C over the course of 12 months of treatment. This suggests that pitavastatin may contribute to reduction in coronary heart disease. © 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:320 / 322
页数:4
相关论文
共 8 条
[1]   Ethical authorship and publishing [J].
Coats, Andrew J. S. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 131 (02) :149-150
[2]   Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I [J].
Crouse, JR ;
Frohlich, J ;
Ose, L ;
Mercuri, M ;
Tobert, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (10) :1476-+
[3]  
GORDON DJ, 1989, NEW ENGL J MED, V321, P1311
[4]   Pitavastatin: efficacy and safety in intensive lipid lowering [J].
Hayashi, Toshio ;
Yokote, Koutaro ;
Saito, Yasushi ;
Iguchi, Akihisa .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (14) :2315-2327
[5]   Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels [J].
Kastelein, JJP ;
Isaacsohn, JL ;
Ose, L ;
Hunninghake, DB ;
Frohlich, J ;
Davidson, MH ;
Habib, R ;
Dujovne, CA ;
Crouse, JR ;
Liu, MZ ;
Melino, MR ;
O'Grady, L ;
Mercuri, M ;
Mitchel, YB .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (02) :221-223
[6]   Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell [J].
Maejima, T ;
Yamazaki, H ;
Aoki, T ;
Tamaki, T ;
Sato, F ;
Kitahara, M ;
Saito, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) :835-839
[7]   Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia [J].
Olsson, AG ;
Istad, H ;
Luurila, O ;
Ose, L ;
Stender, S ;
Tuomilehto, J ;
Wiklund, O ;
Southworth, H ;
Pears, J ;
Wilpshaar, JW .
AMERICAN HEART JOURNAL, 2002, 144 (06) :1044-1051
[8]   High-density lipoprotein as a therapeutic target - A systematic review [J].
Singh, Inder M. ;
Shishehbor, Mehdi H. ;
Ansell, Benjamin J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (07) :786-798